Dose-escalation Study of Afatinib in Elderly Patients with EGFR mutation for Non-Small Cell Lung Cancer
Phase of Trial: Phase I
Latest Information Update: 07 Nov 2016
At a glance
- Drugs Afatinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 31 Oct 2016 Status changed from active, no longer recruiting to completed.
- 28 Aug 2016 Status changed from recruiting to active, no longer recruiting.
- 05 Feb 2015 New trial record